CDKN2A and neoplasm: While PDAC tumors have many low-abundance mutations, there are four dominant driver mutations, namely, oncogenic activation of KRAS and inactivation of the tumor suppressors TP53, CDKN2A, and SMAD4 (Jones et al., 2008).